疑似急性冠脉综合征早期无创心脏检查的成本效益分析
本研究基于Kaiser Permanente南加州综合医疗系统成员的多中心回顾性队列(89,387例,平均57岁,58%女性,19%接受早期NIT),比较早期NIT与无早期NIT的成本与临床结局,并适配成本效益模型计算长期成本和QALYs。结果显示早期NIT总费用增加2357美元(95%CI 77至4821),主要来自首次急诊就诊费用增加;1年随访死亡/非致死性心梗复合风险绝对差为-3.7%(95%CI -4.4%至-3.01%)。支付方视角下早期NIT成本效益比为5268美元/QALY。结论认为在低危和中危患者中具成本效益,在高危患者中为优势策略(节省成本并增加QALYs)。
要点
- 疑似ACS急诊患者接受早期NIT者1年死亡/非致死性心梗复合风险绝对降低3.7%(95%CI -4.4%至-3.01%)。
- 早期NIT使总费用增加2357美元(95%CI 77至4821),主要因首次急诊就诊费用增加。
- 支付方视角下早期NIT成本效益比为5268美元/QALY。
- 在低危和中危患者中早期NIT具成本效益,在高危患者中为优势策略(节省成本并增加QALYs)。
适用人群与场景
- 就诊于急诊科且疑似急性冠脉综合征的患者(多中心回顾性队列,纳入Kaiser Permanente南加州综合医疗系统成员,共89,387例,平均年龄57岁,58%女性)。
研究设计与关键结果
- 多中心回顾性队列纳入89,387例疑似ACS急诊患者,19%接受早期NIT。
- 早期NIT组总费用较无早期NIT组增加2357美元(95%CI 77至4821),主要因首次急诊就诊费用增加。
- 早期NIT与1年随访死亡/非致死性心梗复合风险降低相关,绝对风险差-3.7%(95%CI -4.4%至-3.01%)。
- 支付方视角下早期NIT成本效益比为5268美元/QALY。
- 在低危和中危患者中早期NIT具成本效益,在高危患者中为优势策略(节省成本并增加QALYs)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究结合成本效益模型分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似ACS的急诊患者,采用早期NIT进行风险分层可能降低1年死亡/非致死性心梗复合风险,但会增加总费用,主要来自首次急诊就诊费用增加。
- 支付方视角下,早期NIT在低危和中危患者中具成本效益,在高危患者中为优势策略(节省成本并增加QALYs)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early noninvasive cardiac testing (NIT) is often performed in the initial workup of patients who present to the emergency department (ED) with suspected acute coronary syndrome (ACS). Our study objective was to calculate the cost-effectiveness of adopting early NIT for risk stratification to avoid future nonfatal acute myocardial infarction (MI) or death.
METHODS: To obtain the incremental difference in cost and clinical outcomes, we first conducted a multicenter retrospective cohort study within the member population of the Kaiser Permanente Southern California integrated health care delivery system. We then adapted existing cost effectiveness models to generate long-term costs and quality-adjusted life-years (QALYs) gained by NIT.
RESULTS: The cohort included 89,387 patients (mean age 57 years, 58% female) and 19% received early NIT. Total cost was higher by $2357 (95% confidence interval [CI] $77 to $4821) for early NIT compared to no early NIT and was mainly due to the increased cost of the index ED visit. Early NIT was associated with lower composite risk of death/nonfatal MI (absolute risk difference -3.7%, 95% CI -4.4% to -3.01%) during a 1-year follow-up. From a payor's perspective, early NIT was cost-effective at $5268/QALYs.
CONCLUSIONS: In patients with suspected ACS evaluated in the ED, incorporation of early NIT was associated with an overall increase in cost of health care that was driven by increased cost of the initial ED visit. However, due to the significant clinical benefits, early NIT was cost-effective in the low- and intermediate-risk patients while it is a dominant strategy in high-risk patients saving cost and QALYs.
参考来源
- Kawatkar AA, Thokala P, Goodacre S, et al. Cost-effectiveness of early noninvasive cardiac testing for suspected acute coronary syndrome. Acad Emerg Med. 2025. PMID: 40411283. doi:10.1111/acem.70066
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。